Q-omics provides the consensus-scored BEND5 profile across patient tissues and cancer cell-line models. BEND5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, BEND5 is differentially expressed in 17, with the highest sampling consensus in KICH. Additionally, BEND5 RNA expression shows 17,936 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KICH, and ACC as cancer lineages where BEND5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEND5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEND5 survival associations across molecular data types. BEND5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEND5 RNA expression–survival associations across cancer types. High BEND5 expression shows unfavorable associations in ACC, but favorable associations in LUAD, KIRP, UVM, BRCA and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for BEND5 RNA expression.
This table summarizes BEND5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for BEND5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEND5 shows lower tumor expression in KICH, COAD, KIRP, LUAD, LUSC and THCA. The KICH box plot shows higher BEND5 RNA expression in normal versus tumor tissue (log2 FC = −2.197, t-test p < 0.001).
This table shows molecular features associated with BEND5 in patient tissues and cancer cell lines. In patient samples, BEND5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BEND5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
